Back

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors: pearls from recent trials and surveys Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Ambarish Pandey

University of Texas Southwestern Medical Center, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail
The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study
Assistant Professor E. Maor (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Doctor C. Adamson (Larbert, GB)
Abstract Slides Video
Presentation thumbnail
Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors: pearls from recent trials and surveys

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
thumbnail
Congress Presentation
Broadening the scope: should we implement guideline-directed medical therapy across all left ventricular ejection fraction ranges?
thumbnail
Congress Presentation
Early initiation of disease-modifying therapy in patients with suspected heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources